Savings Experiment: Snow Removal
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Vical Inc. (NASDAQ: VICL) surged higher out of the gate Thursday after scoring a U.S. patent for its pandemic and seasonal influenza vaccines, including those to shield against H1N1 (swine flu) and H5N1 (avian flu). Both treatments use Vical's patented Vaxfectin adjuvant, which helps to boost immunity.
While the H5N1 vaccine has completed early-stage human trials, the H1N1 vaccine has yet to be tested on human subjects. Positive results have been recorded from tests conducted on mice and rabbits, but VICL said earlier this year that it will require more funding to begin large-scale trials on humans.
This morning's trading was looking solid enough and had enough overseas support with gains in Europe that it seemed as though we were going to have a rock solid end to one of the best performing quarters in years. 
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
